Asthma Therapeutics Market Report is a proficient latest research of the Asthma Therapeutics industry comprising of leading manufacturers, product types, and market size revenue forecast. In addition, report sheds light on dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed and includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
Over the 2014–2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to rise at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion touching over $5.6 billion.
Request Sample of Report at: https://www.absolutereports.com/enquiry/request-sample/10111227
High Prevalence and Launch Of Late-Stage Biologics Will Drive the Market In Spite Of Affordability Concerns: Asthma Therapeutics In Asia-Pacific Market Report speaks about Asthma treatment can be classed as either a long-term control medication that is aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Immunomodulators, Inhaled Corticosteroids (ICS), cromolyn sodium, leukotriene modifiers, nedocromil and methylxanthines. Additionally, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs, but not as monotherapies for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab), has been approved as an add-on therapy for treating allergic asthma in the Asia-Pacific region. Nevertheless, significant unmet requirements remain for the treatment of severe eosinophilic asthma.
Asthma is a common chronic inflammatory disease of the airways, which is characterized by recurrent attacks of breathlessness and wheezing. These symptoms vary in frequency and severity for different patients. The exact causes of asthma are still unknown, considering it to be a result of combination of factors, with two major factors thought to be involved are environmental exposure and host factors, particularly genes.
View Full Report of Asthma Therapeutics market: https://www.absolutereports.com/10111227
Opportunities and Scope of Report:
The current Asia-Pacific asthma market in the contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA combination therapy, and Spiriva, a LAMA.
- What are the competitive advantages of the existing novel drugs?
With more than 274 active pipeline molecules, most of the late-stage investigational drug candidates are being examined, with improved dosage regimens and administration routes in comparison to currently marketed products.
- Which classes of novel drugs are most common within the pipeline?
- Is there strong potential for the pipeline to address unmet requirements within the asthma market specifically for severe eosinophilic asthma?
In-depth study of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall rate of attrition for asthma in development being 78%.
- How do failure rates vary based on product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size impact the costs and risks that are associated with the development of product?
- Which markets are making the major contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new entrants lead to substantial changes in annual therapy costs?
- How will various treatment usage patterns impact growth in the five assessed Asia-Pacific markets?
Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.
- Will affordability deter the commercial success of currently existing drugs as well as newly coming biologics?
- Which of the assessed countries have affordability concerns?